drug
fosaprepitant dimeglumine
Marketedupdated 3mo agoby Athenex Inc (Inactive)
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying fosaprepitant dimeglumine
- phase3To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
- phase4Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
- phase3Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 11, 2039
~12.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jan 11, 2039formulationUS 11065265
- Jan 11, 2039formulationUS 12042504
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that